These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 28506237)

  • 1. Clinical and MRI outcome of cervical spine lesions in children with juvenile idiopathic arthritis treated with anti-TNFα drugs early in disease course.
    Ključevšek D; Emeršič N; Toplak N; Avčin T
    Pediatr Rheumatol Online J; 2017 May; 15(1):38. PubMed ID: 28506237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cervical spine involvement in patients with juvenile idiopathic arthritis - MRI follow-up study.
    Hospach T; Maier J; Müller-Abt P; Patel A; Horneff G; von Kalle T
    Pediatr Rheumatol Online J; 2014 Mar; 12():9. PubMed ID: 24593886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: a twelve-year experience.
    Baszis K; Garbutt J; Toib D; Mao J; King A; White A; French A
    Arthritis Rheum; 2011 Oct; 63(10):3163-8. PubMed ID: 21702011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis.
    McMahan R; Balfe LM; Greene L
    J Manag Care Pharm; 2012; 18(1 Suppl B):1-16. PubMed ID: 22376227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis.
    Tynjälä P; Lahdenne P; Vähäsalo P; Kautiainen H; Honkanen V
    Ann Rheum Dis; 2006 Aug; 65(8):1044-9. PubMed ID: 16449314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-year followup study on clinical findings and changes in magnetic resonance imaging-based disease activity scores in juvenile idiopathic arthritis.
    Hemke R; van Veenendaal M; van den Berg JM; Dolman KM; van Rossum MA; Maas M; Kuijpers TW
    J Rheumatol; 2014 Jan; 41(1):119-27. PubMed ID: 24293575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
    Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients.
    Romano M; Pontikaki I; Gattinara M; Ardoino I; Donati C; Boracchi P; Meroni PL; Gerloni V
    Reumatismo; 2014 Mar; 65(6):278-85. PubMed ID: 24705031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamics of serum levels of TNF-α in a longitudinal follow-up study in 98 patients with juvenile idiopathic arthritis treated with anti-TNF-α biological drugs.
    Morozova N; Avramovič MZ; Markelj G; Toplak N; Avčin T
    Clin Rheumatol; 2024 Jul; 43(7):2287-2293. PubMed ID: 38775868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of intraarticular corticosteroid injections in adolescents with juvenile idiopathic arthritis in the temporomandibular joint: a Norwegian 2-year prospective multicenter pilot study.
    Frid P; Augdal TA; Larheim TA; Halbig J; Rypdal V; Songstad NT; Rosén A; Tylleskär KB; Berstad JR; Flatø B; Stoustrup P; Rosendahl K; Kirkhus E; Nordal E
    Pediatr Rheumatol Online J; 2020 Oct; 18(1):75. PubMed ID: 32998740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort.
    Guzman J; Oen K; Tucker LB; Huber AM; Shiff N; Boire G; Scuccimarri R; Berard R; Tse SM; Morishita K; Stringer E; Johnson N; Levy DM; Duffy KW; Cabral DA; Rosenberg AM; Larché M; Dancey P; Petty RE; Laxer RM; Silverman E; Miettunen P; Chetaille AL; Haddad E; Houghton K; Spiegel L; Turvey SE; Schmeling H; Lang B; Ellsworth J; Ramsey S; Bruns A; Campillo S; Benseler S; Chédeville G; Schneider R; Yeung R; Duffy CM;
    Ann Rheum Dis; 2015 Oct; 74(10):1854-60. PubMed ID: 24842571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt.
    Mourão AF; Santos MJ; Melo Gomes JA; Martins FM; Mendonça SC; Oliveira Ramos F; Fernandes S; Salgado M; Guedes M; Carvalho S; Costa JA; Brito I; Duarte C; Furtado C; Lopes A; Rodrigues A; Sequeira G; Branco JC; Fonseca JE; Canhão H
    Rheumatology (Oxford); 2016 Apr; 55(4):697-703. PubMed ID: 26672905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescribing Patterns and Impact of Factors Associated with Time to Initial Biologic Therapy among Children with Non-systemic Juvenile Idiopathic Arthritis.
    Yue X; Huang B; Hincapie AL; Wigle PR; Qiu T; Li Y; Morgan EM; Guo JJ
    Paediatr Drugs; 2021 Mar; 23(2):171-182. PubMed ID: 33651370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis.
    Bichler J; Benseler SM; Krumrey-Langkammerer M; Haas JP; Hügle B
    Scand J Rheumatol; 2015; 44(4):280-3. PubMed ID: 25993023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Juvenile idiopathic arthritis managed in the new millennium: one year outcomes of an inception cohort of Australian children.
    Tiller G; Buckle J; Allen R; Munro J; Gowdie P; Cox A; Akikusa J
    Pediatr Rheumatol Online J; 2018 Nov; 16(1):69. PubMed ID: 30413164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Description of active joint count trajectories in juvenile idiopathic arthritis.
    Berard RA; Tomlinson G; Li X; Oen K; Rosenberg AM; Feldman BM; Yeung RS; Bombardier C
    J Rheumatol; 2014 Dec; 41(12):2466-73. PubMed ID: 25274882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
    Lurati A; Pontikaki I; Teruzzi B; Desiati F; Gerloni V; Gattinara M; Cimaz R; Fantini F
    Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome in juvenile idiopathic arthritis: a population-based study from Sweden.
    Berthold E; Månsson B; Kahn R
    Arthritis Res Ther; 2019 Oct; 21(1):218. PubMed ID: 31661011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS).
    Davies R; Carrasco R; Foster HE; Baildam EM; Chieng SEA; Davidson JE; Ioannou Y; Wedderburn LR; Thomson W; Hyrich KL
    Semin Arthritis Rheum; 2016 Oct; 46(2):190-195. PubMed ID: 27422803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.
    Ruperto N; Lovell DJ; Quartier P; Paz E; Rubio-Pérez N; Silva CA; Abud-Mendoza C; Burgos-Vargas R; Gerloni V; Melo-Gomes JA; Saad-Magalhães C; Sztajnbok F; Goldenstein-Schainberg C; Scheinberg M; Penades IC; Fischbach M; Orozco J; Hashkes PJ; Hom C; Jung L; Lepore L; Oliveira S; Wallace CA; Sigal LH; Block AJ; Covucci A; Martini A; Giannini EH; ;
    Lancet; 2008 Aug; 372(9636):383-91. PubMed ID: 18632147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.